T1	Outcomes 153 212	objective response to chemotherapy using imaging modalities
T2	Outcomes 304 387	serum tumor markers (TMs), namely carcinoembryonic antigen, CA19-9, DUPAN-2, SPan-1
T3	Outcomes 455 502	Monitoring of serum TMs and computed tomography
T4	Outcomes 672 696	fluctuation rates of TMs
T5	Outcomes 872 897	time to progression (TTP)
T6	Outcomes 1162 1188	follows: fluctuation rates
T7	Outcomes 1364 1407	one-month earlier confirmation of treatment
